Jeff Yass’s AnaptysBio ANAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.89M | Buy |
72,500
+67,100
| +1,243% | +$4.07M | ﹤0.01% | 4664 |
|
|
2026
Q1 | $299K | Sell |
5,400
-299,100
| -98% | -$16.1M | ﹤0.01% | 10860 |
|
|
2025
Q4 | $14.8M | Buy |
304,500
+92,800
| +44% | +$3.62M | ﹤0.01% | 2557 |
|
|
2025
Q3 | $6.48M | Buy |
211,700
+114,600
| +118% | +$2.63M | ﹤0.01% | 3682 |
|
|
2025
Q2 | $2.16M | Sell |
97,100
-40,000
| -29% | -$837K | ﹤0.01% | 5635 |
|
|
2025
Q1 | $2.55M | Sell |
137,100
-216,200
| -61% | -$3.61M | ﹤0.01% | 4999 |
|
|
2024
Q4 | $4.68M | Buy |
353,300
+241,400
| +216% | +$5.85M | ﹤0.01% | 3698 |
|
|
2024
Q3 | $3.75M | Buy |
+111,900
| New | +$3.82M | ﹤0.01% | 4127 |
|
|
2023
Q2 | – | Sell |
-31,200
| Closed | -$679K | – | 11992 |
|
|
2023
Q1 | $679K | Sell |
31,200
-2,800
| -8% | -$68K | ﹤0.01% | 7803 |
|
|
2022
Q4 | $1.05M | Buy |
+34,000
| New | +$960K | ﹤0.01% | 6070 |
|
|
2022
Q3 | – | Sell |
-10,100
| Closed | -$205K | – | 13101 |
|
|
2022
Q2 | $205K | Buy |
+10,100
| New | +$224K | ﹤0.01% | 10562 |
|
|
2021
Q4 | – | Sell |
-10,100
| Closed | -$274K | – | 13053 |
|
|
2021
Q3 | $274K | Sell |
10,100
-14,300
| -59% | -$363K | ﹤0.01% | 10792 |
|
|
2021
Q2 | $633K | Sell |
24,400
-104,100
| -81% | -$2.5M | ﹤0.01% | 8988 |
|
|
2021
Q1 | $2.77M | Buy |
+128,500
| New | +$3.24M | ﹤0.01% | 5146 |
|
|
2020
Q4 | – | Sell |
-10,200
| Closed | -$150K | – | 10967 |
|
|
2020
Q3 | $150K | Sell |
10,200
-1,900
| -16% | -$34.3K | ﹤0.01% | 9681 |
|
|
2020
Q2 | $270K | Sell |
12,100
-30,000
| -71% | -$548K | ﹤0.01% | 8534 |
|
|
2020
Q1 | $595K | Sell |
42,100
-55,500
| -57% | -$842K | ﹤0.01% | 6545 |
|
|
2019
Q4 | $1.59M | Sell |
97,600
-126,600
| -56% | -$2.99M | ﹤0.01% | 4697 |
|
|
2019
Q3 | $7.84M | Buy |
224,200
+116,700
| +109% | +$5.55M | ﹤0.01% | 2226 |
|
|
2019
Q2 | $6.07M | Buy |
107,500
+34,500
| +47% | +$2.48M | ﹤0.01% | 2463 |
|
|
2019
Q1 | $5.33M | Sell |
73,000
-12,600
| -15% | -$870K | ﹤0.01% | 2367 |
|
|
2018
Q4 | $5.46M | Buy |
85,600
+9,500
| +12% | +$706K | ﹤0.01% | 2183 |
|
|
2018
Q3 | $7.59M | Buy |
76,100
+2,600
| +4% | +$216K | ﹤0.01% | 2200 |
|
|
2018
Q2 | $5.22M | Sell |
73,500
-310,200
| -81% | -$26M | ﹤0.01% | 2654 |
|
|
2018
Q1 | $39.9M | Buy |
383,700
+246,800
| +180% | +$27.8M | 0.01% | 773 |
|
|
2017
Q4 | $13.8M | Buy |
+136,900
| New | +$10.1M | ﹤0.01% | 1550 |
|
Other funds holding ANAB
EC
TCM
AAA
S
WP
6CM
Jeff Yass's ANAB Position: Q2 2026 in Review
Jeff Yass sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 26,577 shares — an estimated $1.61M sold.
Jeff Yass first reported a position in ANAB in Q4 2017 and held it in 30 quarters. The position peaked at $8.88M in Q1 2018. 211 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.
- Jeff Yass reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
- Jeff Yass sold 26,577 AnaptysBio shares in Q2 2026, an estimated $1.61M.
- Jeff Yass first reported a position in AnaptysBio in Q4 2017 and held it in 30 quarters.
- Jeff Yass's AnaptysBio position peaked at $8.88M in Q1 2018.
- 211 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.